1EW Stock Chart & Stats
€75.42
€1.40(1.89%)
At close: 4:00 PM EDT
€75.42
€1.40(1.89%)
Day’s Range― - ―
52-Week Range€55.00 - €122.00
Previous CloseN/A
Volume0.00
Average Volume (3M)37.00
Market Cap
€43.38B
Enterprise Value€49.95K
Total Cash (Recent Filing)€3.67B
Total Debt (Recent Filing)€702.90M
Price to Earnings (P/E)49.5
Beta0.47
Next Earnings
Oct 28, 2026EPS Estimate
0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding575,800,000
10 Day Avg. Volume7
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)4.82
Price to Sales (P/S)8.22
P/FCF Ratio37.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€90.31Price Target Upside19.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)2.64
Revenue Forecast (FY)€5.95B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityEdwards' persistently high gross and operating margins reflect durable pricing power in premium structural heart devices and efficient cost structure. High margins provide long-term cash generation capacity, funding R&D, buybacks, and cushioning against cyclical procedure volumes.
Conservative Balance SheetVery low leverage gives the company flexibility to invest in innovation, execute buybacks, and withstand reimbursement or procedure-volume shocks. Strong equity base and mid-teens free cash support capital allocation without jeopardizing liquidity or credit profile over the medium term.
Structural Product GrowthRapid TMTT adoption plus steady TAVR growth and clinical/regulatory wins (new devices, CE/approvals, durability data) expand addressable market. A diversified platform across TAVR, mitral, tricuspid and surgical products supports multi-year procedural and consumable-driven revenue growth.
Bears Say
Weaker Cash ConversionWhile still generating positive free cash flow, the deterioration versus the prior year signals variability in converting earnings to cash. Persistent weaker cash conversion could constrain discretionary spend, slow deleveraging or limit reinvestment if the trend persists.
Subdued Revenue TrendLonger-term top-line growth has been inconsistent, with prior-year volatility and low single-digit TTM expansion. Reliance on procedure volumes and timing of new-indication adoption makes revenue less predictable, challenging steady margin and cash-flow improvement targets.
Regulatory & Trial Timing RiskKey policy decisions and trial readouts drive access and broader adoption. Delays or unfavorable outcomes in CMS coverage reconsideration or PROGRESS could slow U.S. uptake and postpone revenue contributions from expanded indications, creating multi-month timing risk to growth trajectories.
Edwards Lifesciences News
1EW FAQ
What was Edwards Lifesciences Corp.’s price range in the past 12 months?
Edwards Lifesciences Corp. lowest stock price was €55.00 and its highest was €122.00 in the past 12 months.
What is Edwards Lifesciences Corp.’s market cap?
Edwards Lifesciences Corp.’s market cap is €43.38B.
When is Edwards Lifesciences Corp.’s upcoming earnings report date?
Edwards Lifesciences Corp.’s upcoming earnings report date is Oct 28, 2026 which is in 87 days.
How were Edwards Lifesciences Corp.’s earnings last quarter?
Edwards Lifesciences Corp. released its earnings results on Jul 23, 2026. The company reported €0.681 earnings per share for the quarter, beating the consensus estimate of €0.649 by €0.032.
Is Edwards Lifesciences Corp. overvalued?
According to Wall Street analysts Edwards Lifesciences Corp.’s price is currently Undervalued.
Does Edwards Lifesciences Corp. pay dividends?
Edwards Lifesciences Corp. does not currently pay dividends.
What is Edwards Lifesciences Corp.’s EPS estimate?
Edwards Lifesciences Corp.’s EPS estimate is 0.64.
How many shares outstanding does Edwards Lifesciences Corp. have?
Edwards Lifesciences Corp. has 575,800,000 shares outstanding.
What happened to Edwards Lifesciences Corp.’s price movement after its last earnings report?
Edwards Lifesciences Corp. reported an EPS of €0.681 in its last earnings report, beating expectations of €0.649. Following the earnings report the stock price went up 1.891%.
Which hedge fund is a major shareholder of Edwards Lifesciences Corp.?
Currently, no hedge funds are holding shares in IT:1EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Company Description
Edwards Lifesciences Corp.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
1EW Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted robust top-line growth led by TMTT (+44.8% YoY) and solid TAVR performance (+10.5% YoY), along with margin expansion and upgraded full-year company and segment guidance. Notable clinical and regulatory milestones (SAPIEN X4S, PROGRESS timeline, PASCAL and M3 approvals/CE Mark, COMMENCE 10-year data) underpin multi-year growth prospects. Offsetting factors include foreign exchange headwinds, higher effective tax rate and GAAP earnings impacts from R&D credit changes, higher SG&A, and tougher second-half comparables creating near-term seasonality and uncertainty. On balance, positive execution, upgraded guidance and strong pipeline/clinical evidence outweigh the near-term financial and macro headwinds.View all IT:1EW earnings summaries1EW Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
1EW Stock 12 Month Forecast
Average Price Target
€90.31
▲(19.75% Upside)